A new study reports that mice shed about 20% of their body weight and saw their breast cancer tumors decrease after getting injected with tirzepatide, which is sold as Mounjaro for diabetes and Zepbound for obesity.
“And while it is very preliminary data, our studies in mice suggest that these new anti-obesity drugs may be a way to reduce obesity-associated breast cancer risk or improve outcomes.”
Tirzepatide is part of a class of GLP-1 drugs, like Ozempic and Wegovy, that reduce appetite by mimicking the GLP-1 hormone the body naturally produces after eating.
